An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7.

Trial Profile

An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Cholangiocarcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Apr 2013 Planned end date changed from 1 Jun 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 24 May 2012 Planned End Date changed from 1 Dec 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top